Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

Widespread use of vancomycin has led to the emergence of isolates that show reduced susceptibility to vancomycin; vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant S. aureus (VRSA) and heteroresistant VISA (hVISA) have been described. The emergence of such strains with conco...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2009-10, Vol.64 (4), p.868-870
Hauptverfasser:	Arhin, Francis F., Sarmiento, Ingrid, Parr, Thomas R., Moeck, Gregory
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Antibiotics Comparative studies Drug resistance glycopeptide non-susceptible Glycopeptides - pharmacology Humans MBCs Microbial Sensitivity Tests MICs Pharmacology Staphylococcal Infections - microbiology Staphylococcus aureus Staphylococcus aureus - drug effects Staphylococcus aureus - isolation & purification Staphylococcus infections Vancomycin Resistance
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Widespread use of vancomycin has led to the emergence of isolates that show reduced susceptibility to vancomycin; vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant S. aureus (VRSA) and heteroresistant VISA (hVISA) have been described. The emergence of such strains with concomitant vancomycin therapeutic failures has necessitated the development of other therapeutic agents.
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkp286